ClinicalTrials.gg
CompletedNCT05698316INTERCEPT-AMDUpdated May 8, 2026

A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression

An observational study in Age Related Macular Degeneration, Intermediate AMD and Atrophy, sponsored by Association for Innovation and Biomedical Research on Light and Image. Completed at 25 sites in 9 countries. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Association for Innovation and Biomedical Research on Light and Image · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Macular Degeneration by Association for Innovation and Biomedical Research on Light and Image — 1 open to participants now, 2 under way, none of them phase 3. Macular Degeneration · Association for Innovation and Biomedical Research on Light and Image.

Started
2023
with 1 other
Observational
8 of 10
1 open now
Registered
9th of 10
by date

Among the 10 studies in Macular Degeneration by Association for Innovation and Biomedical Research on Light and Image, this one is one of 2 that started in 2023, is one of 8 observational ones, and was the 9th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

1 of the 10 studies in Macular Degeneration by Association for Innovation and Biomedical Research on Light and Image is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Macular Degeneration by Association for Innovation and Biomedical Research on Light and Image, or all of them as a file.
02

Study summary

This is a multicentre retrospective and prospective cohort study with the goal to develop a well-characterised multimodal image database of eyes with intermediate AMD with and without early atrophy. The main objectives are:

  1. Develop a collaborative well-characterised database on intermediate AMD with or without early atrophy.
  2. Grading of these images to explore imaging markers of progression.
  3. Develop predictive models as a secondary analysis of our dataset.

This study will recruit around 1.000 eyes in 6 months. All consenting patients who have had at least 3 clinic visits with multimodal imaging done at least at 6 months interval between 2 visits and meet the inclusion and exclusion criteria will be included in the study for retrospective data collection. Those with one visit remaining to complete 2 years, images will be acquired prospectively. In addition to the images, routine demographic data (age and sex) and available visual acuity (VA) (BCVA if possible, VA with Pinhole or VA with patient's glasses) will be collected. Multimodal imaging includes mandated macular OCT with or without enhanced depth imaging and infrared imaging. Fundus autofluorescence (AF) and multicolor imaging are optional. All imaging must be done on Heidelberg Spectralis system.

Read the detailed description

Age-related macular degeneration (AMD) is the commonest cause of visual impairment in older people in Europe. It is a slowly progressing complex disorder. The clinical progression is best described as early, intermediate, and advanced based on the latest classification system on colour fundus photographs. However, multimodal imaging has enabled visualisation of further changes in the retina on optical coherence tomography (OCT), infrared imaging, and autofluorescence. So, a large database of imaging data of intermediate AMD will facilitate researchers to study the disease progression in detail. This study is a collaborative effort by investigators across many Member Sites in Europe that are members of EVICR.net to pool datasets for secondary analysis.

EVICR.net is a network of Ophthalmological Clinical Research Sites, dedicated to performing multinational clinical research in ophthalmology with the highest standards of quality, following the European and International Directives for Clinical Research in order to strengthen the capacity of the European Union to study the determinants of ophthalmic diseases and to develop and optimise the use of diagnostic, prevention and treatment strategies in ophthalmology.

EVICR.net Eye Platform is a long-term initiative to establish a platform to gather high quality ophthalmology data generated in Europe and allow the secondary use of data in performing large data analysis and foster clinical research.

With this Eye Platform EVICR.net aims to provide technological solutions that allow overcoming privacy and regulation issues associated with the sharing of data from different institutions/countries, in a secure, easy to use manner.

With EVICR.net Eye Platform, the Members Sites will have the opportunity to participate in clinical research with secondary use data analysis; Authorship of publications and presentations of Results; the opportunity to propose new analysis to answer key research questions; and increase overall visibility and stature as researchers

Background:

On colour fundus photographs, drusen size and changes in retinal pigment epithelium are used to classify the severity of AMD into early, intermediate and advanced stages.Early AMD is characterised by medium sized drusen of 63 µm to 124 µm with no RPE changes. Intermediate AMD include large drusen (≥125 µm) or medium-sized drusen with pigmentary changes. These eyes with intermediate AMD have a high risk of progression to advanced AMD, including either geographic atrophy or exudative AMD due to macular neovascularisation (MNV). Visual deterioration is seen in these two advanced stages. Therefore, there is an unmet need to identify those at risk of disease progression to advanced AMD so that preventive options can be evaluated and implemented. However, a significant amount of research is required to better understand the risk of disease progression.

With the advent of multimodal imaging, there is growing evidence of new imaging markers of disease progression in eyes with intermediate AMD. For example, on infrared reflectance (IR), optical coherence tomography (OCT) and autofluorescence (AF), subretinal drusenoid deposits (SDD) are seen in some eyes with intermediate AMD and these have been identified as a predictor of fast progression to advanced AMD. Multimodal images have also shown that early atrophic changes may occur in intermediate AMD before the classical diagnosis of atrophy seen as hypoautofluorescence on AF. The Classification of Atrophy Meetings (CAM) group defined a few imaging characteristics as precursors of geographic atrophy and designated them together as incomplete retinal pigment epithelium and outer retinal atrophy (iRORA). A region of signal hypertransmission into the choroid of \<250um, a corresponding zone of attenuation or disruption of the RPE, with or without the persistence of basal laminar deposits (BLamD) and evidence of overlying photoreceptor degeneration, i.e., subsidence of the inner nuclear layer (INL) and outer plexiform (OPL), presence of a hyporeflective wedge in the Henle fiber layer (HFL), thinning of the outer nuclear layer (ONL), disruption of the external limiting membrane (ELM), or disintegrity of the ellipsoid zone (EZ), and when these criteria do not meet the definition of complete retinal pigment epithelium and outer retinal atrophy (cRORA) that defines geographic atrophy on colour photographs. cRORA is defined as zone of hyper transmission of ≥250 µm, zone of attenuation or disruption of RPE band of ≥250 µm with evidence of overlying photoreceptor degeneration characterised by features that include outer nuclear layer (ONL) thinning, external limiting membrane (ELM) loss, and ellipsoid zone (EZ) or interdigitating zone (IZ) loss. Multimodal imaging also showed that drusen sizes on OCT are indeed larger than visualised on colour photographs. On en-face OCT, large drusen is defined as drusen diameter ≥145 µm, medium drusen diameters 100 µm to 144 µm, and small drusen diameters \<100 µm. So, these markers and other novel imaging characteristics may better predict disease progression from intermediate AMD.However, a large multimodal image resource is required to develop such prediction models.

The Heidelberg Spectralis device enables multimodal imaging, and the OCT scans can be segmented by in-built automated Heidelberg software and manually corrected where necessary. So, a large database of Heidelberg imaging data of intermediate AMD will facilitate researchers to study the disease progression in detail.

03

Conditions studied

  • Age Related Macular Degeneration
  • Intermediate AMD
  • Atrophy
  • Prediction
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patient with Age-related macular degeneration (AMD)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each dataset per patient should have one eye as the study eye with:

  • Intermediate AMD with no atrophy and no subretinal drusenoid deposits
  • Intermediate AMD with no atrophy with subretinal drusenoid deposits
  • Intermediate AMD with early atrophy (iRORA) with no Subretinal drusenoid deposits
  • Intermediate AMD with early atrophy (iRORA) with Subretinal drusenoid deposits
  • Intermediate AMD with evidence of cRORA

Non-study eye images will not be exported but information about the status of the macula should be added using the following options:

  • Established Geographic Atrophy (cRORA)
  • Exudative AMD (presence of MNV)
  • Early AMD
  • Healthy macula

Exclusion criteria

Exclusion Criteria:

  • Both eyes have exudative AMD or geographic atrophy at baseline.
  • Co-existent ocular disease: Any other ocular condition that, in the investigator's opinion, might affect or alter visual acuity during the study.
  • Any patient who has opted out of their information being used for research nationally or locally at any Member Site.
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,000 participants (actual)
Patient registry
No

Groups and cohorts

  • Age related macular degeneration

    Collection of both retrospective and prospective data collection in 3 visits.

    Diagnostic Test: Collection of both retrospective and prospective data collection in 3 visits.

Interventions

  • Diagnostic testCollection of both retrospective and prospective data collection in 3 visits.

    3 clinic visits with multimodal imaging done at least at 6 months interval between 2 visits and meet the inclusion and exclusion criteria. Those with one visit remaining to complete 2 years, images will be acquired prospectively. In addition to the images, routine demographic data (age and sex) and available visual acuity (VA) (BCVA if possible, VA with Pinhole or VA with patient's glasses) will be collected. Multimodal imaging includes mandated macular OCT with or without enhanced depth imaging and infrared imaging. Fundus autofluorescence (AF) and multicolor imaging are optional. All imaging must be done on Heidelberg Spectralis system.

06

What researchers measure

Primary outcomes

  1. Incidence of conversion to atrophy at two years

    Number of patients who developed new or increasing atrophy

    Time frame: 24 months

07

Study locations

25 sites
  • Department of Ophthalmology, University Hospital, Nantes
    Nantes, France
  • Department of Ophthalmology University of Bonn
    Bonn, Germany
  • Department of Ophthalmology University of Freiburg
    Freiburg im Breisgau, Germany
  • Department of Ophthalmology Justus/Liebig/University/Giessen
    Giesen, Germany
  • Department of Ophthalmology St. Franziskus/Hospital Münster
    Münster, Germany
  • Department of Ophthalmology University of Muenster Medical Center
    Münster, Germany
  • Eye Clinic Sulzbach, Knappschaft Hospital Saar
    Sulzbach, Germany
  • Royal Victoria Eye and Ear Research Foundation
    Dublin, Ireland
  • Medical Retina Service, Operative Unit Ophthalmology / MultiMedica Spa (IRCCSMM)
    Milan, Italy
  • Eye Unit, University Hospital Maggiore della Carità
    Novara, Italy
  • Department of Ophthalmology University of Udine
    Udine, Italy
  • Department of Ophthalmology Radboud University Medical Centre Nijmegen
    Nijmegen, Netherlands
  • AIBILI-CEC (AIBILI- Clinical Trials Centre)
    Coimbra, Portugal
  • Espaço Médico de Coimbra
    Coimbra, Portugal
  • Instituto de Oftalmologia Dr. Gama Pinto
    Lisbon, Portugal
  • Department of Ophthalmology Porto Medical School / Hospital S. João
    Porto, Portugal
  • Institut Català de Retina (ICR), Clinical Trial Unit
    Barcelona, Spain
  • Institut de la Màcula Centro Médico Teknon
    Barcelona, Spain
  • Valles Ophthalmology Research, S.L.
    Barcelona, Spain
  • Clínica Oftalmológica AIKEN / Fundación Aiken de la Comunitat Valenciana
    Valencia, Spain
  • University Hospital Basel, University Eye Clinic, Basel
    Basel, Switzerland
  • Swiss Visio Retina Research Center, Swiss Visio Montchoisi
    Lausanne, Switzerland
  • Clinical Trial Unit, Dep. Ophth., Gloucestershire Hospitals NHS Foundation Trust
    Cheltenham, United Kingdom
  • Clinical Eye Research Centre - St. Paul's Eye Unit, Royal Liverpool University Hospital
    Liverpool, United Kingdom
  • NIHR Moorfields Clinical Research Facility, Moorfields Eye Hospital, NHS Foundation Trust
    London, United Kingdom
08

References and documents

Publications

  • Ferris FL 3rd, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, Sadda SR; Beckman Initiative for Macular Research Classification Committee. Clinical classification of age-related macular degeneration. Ophthalmology. 2013 Apr;120(4):844-51. doi: 10.1016/j.ophtha.2012.10.036. Epub 2013 Jan 16. PubMed 23332590 ↗
  • Spaide RF, Ooto S, Curcio CA. Subretinal drusenoid deposits AKA pseudodrusen. Surv Ophthalmol. 2018 Nov-Dec;63(6):782-815. doi: 10.1016/j.survophthal.2018.05.005. Epub 2018 May 31. PubMed 29859199 ↗
  • Kim DY, Loo J, Farsiu S, Jaffe GJ. COMPARISON OF SINGLE DRUSEN SIZE ON COLOR FUNDUS PHOTOGRAPHY AND SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY. Retina. 2021 Aug 1;41(8):1715-1722. doi: 10.1097/IAE.0000000000003099. PubMed 33411474 ↗
  • Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC, Blodi BA, Bottoni F, Chakravarthy U, Chew EY, Csaky K, Danis RP, Fleckenstein M, Freund KB, Grunwald J, Hoyng CB, Jaffe GJ, Liakopoulos S, Mones JM, Pauleikhoff D, Rosenfeld PJ, Sarraf D, Spaide RF, Tadayoni R, Tufail A, Wolf S, Staurenghi G. Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3. Ophthalmology. 2018 Apr;125(4):537-548. doi: 10.1016/j.ophtha.2017.09.028. Epub 2017 Nov 2. PubMed 29103793 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Feb 2024, 9 months.

Of 108 non-industry observational studies under Macular Degeneration, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 98. This study's 9 months is below that.

Counting every sponsor, half of 164 studies reached it within 44 months; a quarter within 15 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2023
First posted
Jan 26, 2023
StartActual
May 4, 2023
Primary completionActual
Feb 22, 2024
CompletionActual
Dec 31, 2025
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05698316
Lead sponsor
Association for Innovation and Biomedical Research on Light and Image
Collaborators
European Vision Institute Clinical Research Network
Responsible party
Sponsor
First posted
Jan 26, 2023
Start date
May 4, 2023
Primary completion
Feb 22, 2024
Completion
Dec 31, 2025
Last update
May 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion